NASDAQ:ALPN Alpine Immune Sciences (ALPN) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free ALPN Stock Alerts $38.65 +1.20 (+3.20%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$36.71▼$39.0450-Day Range$18.56▼$41.6052-Week Range$6.71▼$42.88Volume787,120 shsAverage Volume1.29 million shsMarket Capitalization$2.53 billionP/E RatioN/ADividend YieldN/APrice Target$38.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alpine Immune Sciences alerts: Email Address Alpine Immune Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside0.5% Upside$38.86 Price TargetShort InterestBearish8.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 17 Articles This WeekInsider TradingSelling Shares$5,192 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.76) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector725th out of 939 stocksPharmaceutical Preparations Industry334th out of 433 stocks 2.5 Analyst's Opinion Consensus RatingAlpine Immune Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.86, Alpine Immune Sciences has a forecasted upside of 0.5% from its current price of $38.65.Amount of Analyst CoverageAlpine Immune Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.56% of the outstanding shares of Alpine Immune Sciences have been sold short.Short Interest Ratio / Days to CoverAlpine Immune Sciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Alpine Immune Sciences has recently increased by 26.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpine Immune Sciences does not currently pay a dividend.Dividend GrowthAlpine Immune Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALPN. Previous Next 3.8 News and Social Media Coverage News SentimentAlpine Immune Sciences has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Alpine Immune Sciences this week, compared to 3 articles on an average week.Search Interest31 people have searched for ALPN on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.MarketBeat Follows13 people have added Alpine Immune Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,192.00 in company stock.Percentage Held by Insiders42.30% of the stock of Alpine Immune Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.17% of the stock of Alpine Immune Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpine Immune Sciences are expected to decrease in the coming year, from ($1.76) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpine Immune Sciences is -60.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpine Immune Sciences is -60.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpine Immune Sciences has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Alpine Immune Sciences Stock (NASDAQ:ALPN)Alpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ALPN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALPN Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Given Average Rating of "Buy" by BrokeragesMarch 22, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. to Post Q3 2024 Earnings of ($0.50) Per Share, HC Wainwright Forecasts (NASDAQ:ALPN)March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 22, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Alpine Immune Sciences, Inc. Decreased by Analyst (NASDAQ:ALPN)March 22, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Alpine Immune Sciences, Inc.'s Q1 2024 Earnings (NASDAQ:ALPN)March 21, 2024 | finanznachrichten.deAlpine Immune Sciences, Inc.: Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alpine Immune Sciences Amid Positive Povetacicept Trials and Strong Clinical OutlookMarch 21, 2024 | businesswire.comAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 21, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn SituationMarch 21, 2024 | americanbankingnews.comAlpine Immune Sciences, Inc. to Post Q1 2025 Earnings of ($0.52) Per Share, Wedbush Forecasts (NASDAQ:ALPN)March 20, 2024 | seekingalpha.comAlpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | businesswire.comAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2024 | americanbankingnews.comMorgan Stanley Raises Alpine Immune Sciences (NASDAQ:ALPN) Price Target to $47.00March 20, 2024 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Alpine Immune Sciences (NASDAQ:ALPN)March 20, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Earns "Outperform" Rating from OppenheimerMarch 20, 2024 | americanbankingnews.comHC Wainwright Comments on Alpine Immune Sciences, Inc.'s Q1 2024 Earnings (NASDAQ:ALPN)March 20, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Given New $50.00 Price Target at HC WainwrightMarch 20, 2024 | americanbankingnews.comAlpine Immune Sciences (NASDAQ:ALPN) Reaches New 1-Year High Following Analyst UpgradeMarch 19, 2024 | markets.businessinsider.comAlpine Immune Sciences Analysts Boost Their Forecasts After Q4 EarningsMarch 19, 2024 | markets.businessinsider.comEvaluating Alpine Immune Sciences: Insights From 6 Financial AnalystsMarch 19, 2024 | finance.yahoo.comQ4 2023 Alpine Immune Sciences Inc Earnings CallMarch 19, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | americanbankingnews.comShort Interest in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Rises By 9.9%March 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alpine Immune Sciences Amidst Promising Clinical Trials and Forthcoming DataMarch 18, 2024 | investorplace.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q4 2023March 18, 2024 | msn.comAlpine Immune Sciences GAAP EPS of -$0.64, revenue of $58.88MSee More Headlines Receive ALPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALPN CUSIPN/A CIK1626199 Webwww.alpineimmunesciences.com Phone(206) 788-4545Fax303-440-8399Employees126Year FoundedN/APrice Target and Rating Average Stock Price Target$38.86 High Stock Price Target$50.00 Low Stock Price Target$18.00 Potential Upside/Downside+0.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,180,000.00 Net Margins-54.66% Pretax Margin-54.49% Return on Equity-15.54% Return on Assets-11.34% Debt Debt-to-Equity RatioN/A Current Ratio7.86 Quick Ratio7.86 Sales & Book Value Annual Sales$58.88 million Price / Sales43.03 Cash FlowN/A Price / Cash FlowN/A Book Value$5.64 per share Price / Book6.85Miscellaneous Outstanding Shares65,550,000Free Float37,820,000Market Cap$2.53 billion OptionableOptionable Beta1.13 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Mitchell H. Gold M.D. (Age 56)Executive Chairman & CEO Comp: $778.2kDr. Stanford Peng M.D. (Age 53)Ph.D., President and Head of Research & Development Comp: $751.2kMr. Paul Rickey (Age 45)Senior VP, CFO, Treasurer & Secretary Comp: $577.1kMs. M. Christina Yi (Age 47)Chief Technology Officer Temre JohnsonHead of IR & Corporate CommunicationsDr. Remy Durand Ph.D. (Age 39)Chief Business Officer Dr. Wolfgang Dummer M.D. (Age 58)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTTG TherapeuticsNASDAQ:TGTXKeros TherapeuticsNASDAQ:KROSRhythm PharmaceuticalsNASDAQ:RYTMCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsHighPoint Advisor Group LLCBought 15,190 shares on 3/26/2024Ownership: 0.023%Vanguard Group Inc.Bought 759,888 shares on 3/11/2024Ownership: 3.846%Wellington Management Group LLPBought 70,151 shares on 3/5/2024Ownership: 0.189%American International Group Inc.Bought 343 shares on 2/28/2024Ownership: 0.028%Price T Rowe Associates Inc. MDBought 290,834 shares on 2/16/2024Ownership: 2.904%View All Insider TransactionsView All Institutional Transactions ALPN Stock Analysis - Frequently Asked Questions Should I buy or sell Alpine Immune Sciences stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALPN shares. View ALPN analyst ratings or view top-rated stocks. What is Alpine Immune Sciences' stock price target for 2024? 7 brokerages have issued 1 year target prices for Alpine Immune Sciences' shares. Their ALPN share price targets range from $18.00 to $50.00. On average, they anticipate the company's stock price to reach $38.86 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for ALPN or view top-rated stocks among Wall Street analysts. How have ALPN shares performed in 2024? Alpine Immune Sciences' stock was trading at $19.06 at the beginning of the year. Since then, ALPN shares have increased by 102.8% and is now trading at $38.65. View the best growth stocks for 2024 here. Are investors shorting Alpine Immune Sciences? Alpine Immune Sciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,610,000 shares, an increase of 26.6% from the February 29th total of 4,430,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 5.1 days. View Alpine Immune Sciences' Short Interest. When is Alpine Immune Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALPN earnings forecast. How were Alpine Immune Sciences' earnings last quarter? Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to analysts' expectations of $22.30 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%. What ETF holds Alpine Immune Sciences' stock? AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio. What other stocks do shareholders of Alpine Immune Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN). Who are Alpine Immune Sciences' major shareholders? Alpine Immune Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Decheng Capital LLC (12.19%), Great Point Partners LLC (6.37%), Frazier Life Sciences Management L.P. (5.39%), Vanguard Group Inc. (3.85%), Vanguard Group Inc. (3.85%) and Price T Rowe Associates Inc. MD (2.90%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway. View institutional ownership trends. How do I buy shares of Alpine Immune Sciences? Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALPN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.